Abstract
Ciliary neurotrophic factor (CNTF) is a cytokine with neurotrophic activity across a broad spectrum of peripheral and central nervous system (CNS) cells. While its therapeutic potential for CNS diseases has been clear for sometime, the blood brain barrier (BBB) hinders the systemic delivery of CNTF and direct bolus injections are not suitable due to the short half-life of CNTF. One means of overcoming the BBB while providing continuous delivery of CNTF is with immunoisolated cellular implants that produce and deliver CNTF directly to the region of interest. Cells can be protected from host rejection by encapsulating, or surrounding, them within an immunoisolatory, semipermeable membrane that admits oxygen and required nutrients and releases bioactive cell secretions, but restricts passage of larger cytotoxic agents from the host immune defense system. The selective membrane eliminates the need for chronic immunosuppression of the host and allows the implanted cells to be obtained from nonhuman sources. In this review we discuss cell immunoisolation for Huntingtons disease and retinitis pigmentosa. These two indications are highlighted because of extensive pre-clinical data supporting the general concept and recent clinical data that both strengthens the theoretical role of CNTF for treating neurodegeneration and justifies additional clinical evaluation in these and other diseases.
Keywords: cell survival, amyotrophic lateral sclerosis (ALS), GABAergic, neuroprotective, Baby hamster kidney fibroblast cells (BHK), Transplanted Cells
Current Gene Therapy
Title: Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa
Volume: 6 Issue: 1
Author(s): Dwaine F. Emerich and Christopher G. Thanos
Affiliation:
Keywords: cell survival, amyotrophic lateral sclerosis (ALS), GABAergic, neuroprotective, Baby hamster kidney fibroblast cells (BHK), Transplanted Cells
Abstract: Ciliary neurotrophic factor (CNTF) is a cytokine with neurotrophic activity across a broad spectrum of peripheral and central nervous system (CNS) cells. While its therapeutic potential for CNS diseases has been clear for sometime, the blood brain barrier (BBB) hinders the systemic delivery of CNTF and direct bolus injections are not suitable due to the short half-life of CNTF. One means of overcoming the BBB while providing continuous delivery of CNTF is with immunoisolated cellular implants that produce and deliver CNTF directly to the region of interest. Cells can be protected from host rejection by encapsulating, or surrounding, them within an immunoisolatory, semipermeable membrane that admits oxygen and required nutrients and releases bioactive cell secretions, but restricts passage of larger cytotoxic agents from the host immune defense system. The selective membrane eliminates the need for chronic immunosuppression of the host and allows the implanted cells to be obtained from nonhuman sources. In this review we discuss cell immunoisolation for Huntingtons disease and retinitis pigmentosa. These two indications are highlighted because of extensive pre-clinical data supporting the general concept and recent clinical data that both strengthens the theoretical role of CNTF for treating neurodegeneration and justifies additional clinical evaluation in these and other diseases.
Export Options
About this article
Cite this article as:
Emerich F. Dwaine and Thanos G. Christopher, Intracompartmental Delivery of CNTF as Therapy for Huntingtons Disease and Retinitis Pigmentosa, Current Gene Therapy 2006; 6 (1) . https://dx.doi.org/10.2174/156652306775515547
DOI https://dx.doi.org/10.2174/156652306775515547 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Current Drug Targets - CNS & Neurological Disorders Reactive Oxygen Species, Redox Signaling and Neuroinflammation in Alzheimer's Disease: The NF-κB Connection
Current Topics in Medicinal Chemistry Biotransformation of Microcystins in Eukaryotic Cells - Possible Future Research Directions
Mini-Reviews in Medicinal Chemistry Jatrorrhizine Protects Against Okadaic Acid Induced Oxidative Toxicity Through Inhibiting the Mitogen-Activated Protein Kinases Pathways in HT22 Hippocampal Neurons
CNS & Neurological Disorders - Drug Targets Gene Transfer with Sequence-Defined Oligo(ethanamino)amides Bioreducibly Attached to a Propylenimine Dendrimer Core
Pharmaceutical Nanotechnology Polypharmacology of Approved Anticancer Drugs
Current Drug Targets Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions
Current Drug Targets p35 Deficiency Accelerates HMGB-1-mediated Neuronal Death in the Early Stages of an Alzheimer's disease Mouse Model
Current Alzheimer Research Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Nicotine, Body Weight and Potential Implications in the Treatment of Obesity
Current Topics in Medicinal Chemistry Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology
Current Pharmaceutical Design Editorial [Hot topic: Sigma1 and Sigma 2 Receptors (Guest Editor: Richard A. Glennon)]
Central Nervous System Agents in Medicinal Chemistry A Quantitative Proteomic Analysis to Reveal Effects of N-acetylcysteine on H<sub>2</sub>O<sub>2</sub>-induced Cytotoxicity
Current Proteomics From Head to Tail: Microwave-Assisted Synthesis of Para Hydrazine Nicotinamide Phenylalanine8-Oxytocin Derivatives
Letters in Organic Chemistry